Processa Pharmaceuticals, Inc. (PCSA) Stock Price & Analysis
Processa Pharmaceuticals, Inc. (PCSA) fell 15.91% to USD 2.04 as of June 10, 2026 at 07:49 UTC, according to Nexqual real-time market data.
PCSA last closed at USD 2.42; the session ranged USD 1.93–2.58 on volume of 108,543 shares. Market capitalization is $5.60M, with a 52-week range of USD 1.76–19.63 (NCM). Source: Nexqual, June 10, 2026 at 07:49 UTC.
Key Statistics (as of June 10, 2026 at 07:49 UTC)
| Price | USD 2.04 |
|---|---|
| Change | ▼ 15.91% (down) |
| Previous Close | USD 2.42 |
| Open | USD 2.45 |
| Day Range | USD 1.93 – 2.58 |
| 52-Week Range | USD 1.76 – 19.63 |
| Volume | 108,543 shares |
| Market Cap | $5.60M |
| Exchange | NCM |
Technical Analysis (PCSA)
Nexqual's technical model rates PCSA "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 07:49 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 42.99 (neutral) |
| vs SMA50 | Below (USD 2.75) |
| MACD | -0.04 (negative) |
Analyst Ratings (PCSA)
Wall Street analysts rate PCSA "None", per Nexqual as of June 10, 2026 at 07:49 UTC.
| Consensus Rating | None |
|---|
Earnings (PCSA)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-09-30 | USD -1.75 vs est -2 ▲ beat |
| 2025-06-30 | USD -6.25 vs est -5.75 ▼ miss |
| 2025-03-31 | USD -7.5 vs est -19.25 ▲ beat |
| 2024-12-31 | USD -18.5 vs est -23 ▲ beat |
Source: Nexqual, June 10, 2026 at 07:49 UTC.
Financials & Fundamentals (PCSA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -464.99% |
| Current Ratio | 0.98 |
| Total Cash | $1.69M |
| Total Debt | $0 |
| Free Cash Flow | $-6.83M |
Source: Nexqual, June 10, 2026 at 07:49 UTC.
Financial Health Score (PCSA)
Nexqual rates Processa Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 07:49 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $2M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$12M |
| Efficiency | Critical — ROE -465%, ROA -193.9% |
Ownership (PCSA)
| Insider Ownership | +14.14% |
|---|---|
| Institutional Ownership | +10.31% |
| Shares Outstanding | 2.75M |
| Float | 2.48M |
| Short % of Float | +3.81% |
Source: Nexqual, June 10, 2026 at 07:49 UTC.
Leadership (PCSA)
Processa Pharmaceuticals, Inc. is led by George K. Ng Esq. (age 51), CEO & Director, per Nexqual as of June 10, 2026 at 07:49 UTC.
| CEO & Director | George K. Ng Esq. (age 51) |
|---|---|
| Chief Financial Officer | Russell L. Skibsted (age 66) |
| Co-Founder, President of Research and Development & Director | David Young Ph.D., Pharm.D. (age 72) |
| Senior Vice President of Clinical Research | Steven Cha |
Major Backers & Investors (PCSA)
Notable institutional backers of Processa Pharmaceuticals, Inc. include Connective Capital Management LLC, Stonepine Capital Management, LLC, Fidelity, according to Nexqual as of June 10, 2026 at 07:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Connective Capital Management LLC | 2.57% |
| Stonepine Capital Management, LLC | 2% |
| Fidelity | 0.74% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.31% |
| Geode Capital | 0.91% |
Source: Nexqual, June 10, 2026 at 07:49 UTC.
From Processa Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-18)
Key Strengths & Strategy (as disclosed to the SEC)
- Capecitabine Market Size - By Indication (Breast, Colorectal, Gastric, Pancreatic), By Synthesis Type (Chemical Based API, Biological API, Highly Potent API, Mode, Global Forecast 2023- 2032 .
- North America Capecitabine Market Research Report - Segmented By Application, Drug Formulation & Country (U.S, Canada & Rest of North America) - Industry Analysis, Size, Share, Growth, Trends, & Forecasts (2024 to 2032) .
- We then efficiently develop our pipeline of Next Generation Cancer therapies utilizing our proprietary Regulatory Science Approach, which we believe will further increase the likelihood of regulatory approval.
- We believe our approach will extend survival and improve quality of life for many patients fighting cancer.
Partnerships
- We are also required to split any sales milestone payments or royalties we receive with Aposense based on any sub-license agreement we may enter.   License Agreement with Yuhan Corporation   On August 19, 2020, we entered into a License Agreement with Yuhan Corporation ("Yuhan License Agreement"), pursuant to which we acquired an exclusive license to develop, manufacture and commercialize PCS12852 globally, excluding South Korea.
- Sian Bigora, developed trade secrets and know-how developed from the regulatory science research initially developed in collaboration with FDA and later refined by Drs.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SPRC | SciSparc Ltd. | USD 9.31 | ▼ 18.62% |
| FEMY | Femasys Inc. | USD 5.25 | ▼ 14.22% |
| ZVSA | ZyVersa Therapeutics, Inc. | USD 0.17 | ▼ 12.55% |
| PALI | Palisade Bio, Inc. | USD 1.69 | ▼ 2.87% |
| LIXT | Lixte Biotechnology Holdings, I | USD 6.87 | ▼ 1.86% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:49 UTC. This page is informational and not investment advice.